K. Persaud

发表

Backbone flexibility of CDR3 and immune recognition of antigens.

Zhiping Weng, Wei Zhu, Brian G. Pierce, 2014, Journal of molecular biology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.

M. Skobe, D. Hicklin, M. Swartz, 2005, Journal of the National Cancer Institute.

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

J. Haidar, M. Kalos, S. Eastman, 2020, Cancer Immunology Research.

Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

R. Dana, Yan Wu, K. Persaud, 2006, Proceedings of the National Academy of Sciences of the United States of America.

A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation

Zhen-ping Zhu, S. Eastman, Haifan Zhang, 2015, mAbs.

Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies*

P. Bohlen, Zhen-ping Zhu, P. Kussie, 2000, The Journal of Biological Chemistry.

Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

P. Bohlen, K. Persaud, Z. Zhu, 1999, Journal of immunological methods.

Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.

K. Alitalo, D. Hicklin, Takashi Takahashi, 2007, Cancer research.

Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C

Zhen-ping Zhu, K. Persaud, J. Tille, 2004, Journal of Cell Science.

Kaposi's Sarcoma-associated Herpesvirus Activation of Vascular Endothelial Growth Factor Receptor 3 Alters Endothelial Function and Enhances Infection*

B. Chandran, J. Groopman, K. Persaud, 2005, Journal of Biological Chemistry.

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhen-ping Zhu, Yan Wu, D. Ludwig, 2010, Clinical Cancer Research.

Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.

M. Skobe, Yan Wu, K. Persaud, 2006, Cancer research.

The structural basis for the function of two anti-VEGF receptor 2 antibodies.

P. Kussie, Leyi Shen, Amtul Bari, 2011, Structure.

A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth

K. Persaud, K. Paz, K. Credille, 2014, Cancer biology & therapy.

Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity

Aiping Zhu, D. Ludwig, Amtul Bari, 2013, mAbs.

A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3

Dan Lu, Zhen-ping Zhu, K. Persaud, 2005, Molecular Cancer Therapeutics.

Development of a novel and efficient cell culture flocculation process using a stimulus responsive polymer to streamline antibody purification processes

James Hamzik, Nripen Singh, Michael Felo, 2013, Biotechnology and bioengineering.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Zhen-ping Zhu, Haifan Zhang, D. Ludwig, 2009, Neoplasia.

IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.

Xenia Luna, Dipa Patel, Xiaoqiang Kang, 2010, Human antibodies.

162 In vivo effects of a monoclonal antibody to the murine VEGFR-3 that antagonizes the binding of VEGF-C and receptor signaling

D. Hicklin, M. Swartz, K. Persaud, 2004 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.